0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TNFSF11

TNFSF11

TNFSF11 Molecule Information

Name:Tumor necrosis factor ligand superfamily member 11
Target Synonym:Osteoprotegerin ligand;CD_antigen=CD254;Tumor necrosis factor ligand superfamily member 11;ODF;Tumor necrosis factor ligand superfamily member 11, membrane form;Osteoclast differentiation factor;TNFSF11;TRANCE;RANKL;Tumor necrosis factor ligand superfamil
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:21
Lastest Research Phase:Approved

TNFSF11 Part of Bioactivity data

RAL-H5265-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

RAL-H5240-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-TNFSF11 (human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNFSF11, His Tag (active trimer) (Cat. No. RAL-H5240) with an affinity constant of 0.274 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

TNFSF11 Protein Product ListCompare or Buy

TNFSF11 Molecule Synonym Name

RANKL,CD254,TRANCE,OPGL,ODF

TNFSF11 Molecule Background

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

TNFSF11 References

TNFSF11 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Denosumab AMG-162; NSC-744010,AMG162 Approved Amgen, Daiichi Sankyo denosumab ema Amgen Europe B.V. 2010-05-26 Bone cancer, Bone metastases from solid tumors, Solid tumours, Multiple myeloma (MM), Giant cell tumor of bone, Hypercalcemia, Rheumatoid arthritis (RA), Osteoporosis Details

TNFSF11 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALX-0141 ALX-0141; EDP-406 Phase Ⅰ Ablynx, Eddingpharm Bone disorders, Postmenopausal osteoporosis Details
Recombinant human anti-RANKL antibody(Shanghai Henlius Biotech) HLX14,HLX-14 Phase Ⅰ Shanghai Henlius Biotech Postmenopausal osteoporosis Details
RPH-203 RPH-203 Phase Ⅰ R-Pharm Bone cancer, Osteoporosis Details
Recombinant human anti-RANKL antibody (Innovent Biologics) IBI-307,IBI307 Phase Ⅰ Innovent Biologics Osteoporosis Details
APX-008 APX-008 Preclinical Epitomics, Apexigen Bone disorders Details
Recombinant anti-RANKL human monoclonal antibody (Salubris) IND Filing Salubris Cancer Details
Denosumab biosimilar (Sandoz) GP-2411 Phase Ⅲ Sandoz, Novartis Postmenopausal osteoporosis Details
Denosumab biosimilar (Intas Biopharmaceuticals) Phase Ⅲ Intas Biopharmaceuticals Postmenopausal osteoporosis Details
Recombinant aiti-RANKL human monoclonal antibody (Kunming Pharmaceutical) IND Filing Kunming Pharmaceutical Cancer Details
JMT103 JMT-103,JMT103; JMT 103 Phase Ⅰ Shanghai Jinmante Biological Technology, China Shijiazhuang Pharmaceutical Group/CSPC Osteoporosis Details
Denosumab biosimilar (AryoGen) Phase Ⅲ AryoGen Biopharma Postmenopausal osteoporosis Details
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) Phase Ⅲ Qilu Pharmaceutical Postmenopausal osteoporosis Details
Recombinant human anti-RANKL antibody (Alphamab) KN-012,KN012 IND Filing Alphamab Osteoporosis Details
Recombinant human anti-RANKL momoclonal antibody (Hualan Biological Engineering) Phase Ⅰ Hualan Biological Engineering Bone metastases from solid tumors Details
GB-223 GB-223,GB223 Phase Ⅰ Genor Biopharma Bone metastases from solid tumors, Giant cell tumor of bone, Postmenopausal osteoporosis Details
Denosumab biosimilar (Qilu Pharma) QL-1206 Phase Ⅲ Qilu Pharmaceutical Bone metastases from solid tumors Details
Denosumab biosimilar (Boan Biopharma/Luye Pharma) LY-01011; LY-06006,LY 01011; LY 06006 Phase Ⅲ Shandong Boan Biotechnology, Luye Pharma Bone metastases from solid tumors, Multiple myeloma (MM), Postmenopausal osteoporosis, Osteoporosis Details
CEP-37251 ART-010; CEP-37251; EGX-010 Phase Ⅰ Teva Osteoporosis Details
LZM-004 LZM-004,LZM004 Phase Ⅰ Livzon Group Livzon Pharmaceutical Factory Bone metastases from solid tumors, Osteoporosis Details
AP-002 AP-003; AP-002; LX-001 Phase Ⅱ Altum Pharmaceuticals Solid tumours Details
Recombinant human anti-RANKL antibody (Hisun Pharma) HS629 Phase Ⅰ Hisun Pharm Bone metastases from solid tumors Details
Recombinant human anti-RANKL antibody (Jiangsu T-mab BioPharma) TK-006; MW032; MW031,TK006 Phase Ⅲ Jiangsu T-mab BioPharma Bone metastases from solid tumors Details

This web search service is supported by Google Inc.

totop